Reports Q4 revenue $4.56B, consensus $4.42B. “2024 was one of the best years in the history of Boston Scientific (BSX), fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Notable companies reporting before tomorrow’s open
- Boston Scientific price target raised to $115 from $110 at TD Cowen
- Boston Scientific price target raised to $115 from $95 at Piper Sandler
- Boston Scientific (BSX) Q4 Earnings Cheat Sheet
- Boston Scientific price target raised to $119 from $101 at Raymond James
Questions or Comments about the article? Write to editor@tipranks.com